SOURCE: CLX Medical, Inc.

April 21, 2008 11:39 ET

CLX Investment Company Announces Implementation of New Corporate Name - CLX Medical, Inc.

Company Will Immediately Begin Branding Efforts to Reflect Focus on Multiple Products in the Medical Diagnostic Testing Market

MURRIETA, CA--(Marketwire - April 21, 2008) - CLX Investment Company, Inc. (OTCBB: CLXN), which owns 51% of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets, today announced that the company has begun operating under its new corporate name, CLX Medical, Inc.

The change was initiated to more accurately reflect CLX's current focus and expected future as a leader in the launch of medical diagnostic testing products. CLX is currently preparing to initiate clinical trials for Zonda's HandiLab-C test for Chlamydia as part of the process to achieve FDA clearance for the product. With FDA clearance, CLX will seek to achieve widespread distribution for the HandiLab-C within the U.S., as well as broader distribution into worldwide markets.

In addition to Zonda's Chlamydia product, CLX recently announced that the company has identified a rapid diagnostic device for the medical market that it has targeted for potential acquisition. As additional due diligence and negotiations are undertaken, the company expects to enter into an initial agreement in the form of a letter of intent for the acquisition of the device. CLX has stated as its core focus to seek additional products and technologies for the company to become involved with as they are presented.

A Schedule 14C Information Statement was filed with the Securities and Exchange Commission on April 9, 2008 reporting majority shareholder approval on the proposal to change the company's name.

According to information the company has received since filing the information statement, the company's CUSIP number will remain the same, and the Board believes that CLX's stock trading symbol will also remain the same.

"As we prepare to begin the clinical trials for the Zonda Chlamydia product and move forward with the acquisition of another rapid diagnostic testing device, changing the company's name to CLX Medical, Inc. will help to identify CLX within the medical supply industry," stated Vera Leonard, chief executive officer of Zonda and CLX. "Shareholders should now look for additional information related to the operations of CLX, including our acquisition candidate and the validation study for Zonda's Chlamydia test."

To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.

About CLX Investment Company

CLX Investment Company (www.clxinvestments.com) holds a 51% equity interest in Zonda, Inc. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments, are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact Information

  • Contact:
    Gemini Financial Communications
    A. Beyer
    951-677-8073
    Email Contact